THEORETIC AND EXPERIMENTAL SUBSTANTIATION OF A COMPOSITION OF A CREAM WITH CERIUM DIOXIDE NANOPARTICLES

Relevance. Cutaneous malignancies are one of the most widespread form of cancer with increasing prevalence and Ukraine and worldwide. A negative impact of ultraviolet radiation is one of the risk factors of this pathology, and it can be prevented by photoprotectors. It is expedient to develop a new effective and safe sunscreen with cerium dioxide nanoparticles, which is deprived of photocatalytic properties and has prominent photoprotective and antioxidant action. Objective: theoretic and experimental substantiation of a composition of a cream with cerium dioxide nanoparticles by the means of a screening of photoprotective action on a model of a photodynamic injury in guinea pigs with further identification of a leader cream. Material and methods. A photodynamic injury in guinea pigs was modeled with ultraviolet emitter with an exposition of 5 minimal erythema doses. Twenty minutes prior to exposure a cream with 0.1%, 0.25% or 0.5% cerium dioxide nanoparticles or a comparator cream with 3% titanium dioxide was applied topically. A leader cream was then chosen based on the following criteria: photoprotective action, skin temperature, blood leukocyte count, and serum histamine level. Results. The cream with 0.25% cerium dioxide nanoparticles was identified as a leader cream, because its photoprotective action was 43.6%, compared to 23.1% and 35.9% for 0.1% and 0.5% creams, respectively. After an application of the cream with 0.25% cerium dioxide nanoparticles there were less ulcers and deep skin lesions and 17.4% less leukocytosis than in pathology control group; the lowest increase (0.16 °С) in skin temperature was observed in comparison with other test creams; no increase in serum histamine level was detected. The cream with 0.25% cerium dioxide nanoparticles was more effective than a comparator. Four hours post-exposure there was 57.1% less pronounced erythema in the leader cream group than in the cream with 3% titanium dioxide group. photoprotective action of a comparator was only 23.1%. Skin temperature in a comparator group 4 hours post-exposure was 0.26 °С higher than in the cream with 0.25% cerium dioxide nanoparticles group. Moreover, 8.6% more pronounced leukocytosis was observed in the cream with 3% titanium dioxide group, compared to the leader cream group. Conclusions. The cream with cerium dioxide nanoparticles 0.25% was recognized as the leading sample and recommended for choosing technology and final composition of the finished dosage form, for further in-depth pharmacological study by totality of studied parameters.

The Effect of Curcumin On Plasma Histamine Level, PEF Variation and Length of Stay of Patients With Acute Exacerbation Asthma

Introduction: Inflammation in asthma occured in airway especially in submucous layer, and involve eosinophil, neutrophil, lymphocytes T, epitheliat cel, basophil, mast cell, and lymphocytes B. Inflammatory cells produce inflammatory mediators (histamine, leucotrienes, and prostanoid), cytokines, and chemokines that can cause bronchocontriction. This study was conducted to determine and prove the effect of curcumin as adjunctive therapy in acute exacerbation asthma. Curcumin is expected to increase the quality therapy of acute exacerbation asthma. The effect of curcumin is known wiith evaluate plasma histamine level, PEF variation, and length of stay of patient with acute exacerbation asthma. Methods: This study is a quasi experimental study with pretest and posttest design. Sampel of study is 30 patients hospitalizes acute exacerbation asthma in Moewardi hospital and Sohadi Prijonegoro Sragen hospital in August 2016 until september 2016. The subject was taken with concecutive random sampling. Independent variable is curcumin 4x550 mg and dependent variables are plasma histamin level, PEF variation, and length of stay. Result: There is no significant difference (P=0.462) of decreasing plasma histamine level between treatment group 3,988±2,739 ng/ml and control group 3,376±1,606 ng/ml. There is no significant difference (P=0.501) of PEF variation between treatment group 28,126±7,886% and control group 30,400±10,217%. There is no significant difference (P=0.936) of length of stay between treatment group perlakuan 6,333±2,193 days and control group 6,400±2,292 days. Conclusion: Giving curcumin in acute exacerbation asthma while hospitalized didn’t reduce inflammatory marker plasma histamin, PEF variation, and length of stay. (J Respir Indo 2018; 38(2): 100-8)